SUCEESSFUL TREATMENT OF 19 YEAR OLD WITH AVM USING CYBERKNIFE
CASE HISTORY: This 19 years old college student presented with the complaints of acute onset headache, right hemiparesis and right hemianopia. MRI revealed haemorrhagic infart in left inferior thalamus extending to capsule and old left posterior capsular infart. DSA revealed left temporal AVM (feeder Medial lenticulostride branches of Left MCA draining into vein of galen through basal vein. On examination patient had right hemianopia. Patient underwent treatment with cyber knife radio surgery on 22.6.2009. Patient is on regular follow up with Volume analysis which showed good regression of nidus. January 2011 CT angio revealed complete resolution of AVM. Patient’s vision has dramatically improved.
This 19 year old girl is now 21 years, she is also entering into married life soon. We wish her a very happy married life.
DOCTOR NAME: DR. RATHNA DEVI SR. CONSULTANT RADIATION ONCOLOGIST & CYBERKNIFE SERVICES
For more information you may blog your comments or write to lakshmipriya_b@apollohospitals.com
Thursday, February 9, 2012
Cyberknife Radiation Successful For Treating Tigeminal Neuralgia
Cyberknife Radiation Successful For Treating Tigeminal Neuralgia
A small study published online in the Journal of NeuroInterventional Surgery shows that a technique in which highly concentrated beams of radiation are used, known as Cyberknife, can relieve the stabbing pain of the facial nerve condition trigeminal neuralgia.
For their study, the researchers treated 17 patients with trigeminal neuralgia between the ages of 36 and 90, with Cyberknife radio surgery between 2007 and 2009. All patients had suffered between 1 and 11 years from the condition and failed to respond to common methods of treatment.
The treatment consisted of zapping a maximum radiation dose of 73.06 Gy into a 6mm length of the trigeminal nerve, just 2 to 3mm from the root, after which the patients were frequently monitored for an average period of just less than 12 months.
Whist 14 patients reported either a partial or complete relief of symptoms; complete data was available for 16 patients. The average time before the symptoms were relieved was slightly less than two months, with variations from three weeks to half a year. The researchers noted a relapse after the procedure in four patients, occurring between 3 and 18 months later.
None of the patients reported any major complications as a result of the procedure, with only two patients reporting any sensory side effects. The researchers conclude that radio surgery provides a viable alternative to more invasive approaches and should be further investigated.
Written by Petra Rattue
Copyright: Medical News Today
Source: http://www.medicalnewstoday.com/articles/240938.php
To know more about cyberknife you may please reply with your comment or write to lakshmipriya_b@apollohospitals.com
Wednesday, November 16, 2011
Glomus Jugulare Tumour successfully treated with cyberknife
MEDICAL REPORT
This 41 years old gentleman a case of glomus jugulare tumour was diagnosed in 2005. He underwent embolisation in 15.03.2005 followed by excision of tumour on 18.03.2005 at Kerala.
On follow up in 5.05.2005 MRI showed residual lesion of size 3.4 x2.2 cm. Patient underwent SRS on 26.07.2005 for a dose of 10 Gy to 80% isodose at elsewhere.
On follow up found recurrence in 2007 for which he went to same center where no further treatment was offered.
Then he went to another hospital in Kerala where he was offered 2nd open surgery for which patient was not willing. Then in April 2010 MRI done showed increase in lesion size about 4.3 cm x 4.21 cm x6.0 cm in size.
TREATMENT
Patient came to Apollo speciality bospital for further treatment. Patient was treated with Cyberknife boost and IMRT after discussion through our tumour board
Now follow MRI revealed good regression of size of tumour and volume analysis showed almost close to 40 to 50 % of reduction in tumour volume.
For more information you may blog your comments or write to lakshmipriya_b@apollohospitals.com
This 41 years old gentleman a case of glomus jugulare tumour was diagnosed in 2005. He underwent embolisation in 15.03.2005 followed by excision of tumour on 18.03.2005 at Kerala.
On follow up in 5.05.2005 MRI showed residual lesion of size 3.4 x2.2 cm. Patient underwent SRS on 26.07.2005 for a dose of 10 Gy to 80% isodose at elsewhere.
On follow up found recurrence in 2007 for which he went to same center where no further treatment was offered.
Then he went to another hospital in Kerala where he was offered 2nd open surgery for which patient was not willing. Then in April 2010 MRI done showed increase in lesion size about 4.3 cm x 4.21 cm x6.0 cm in size.
TREATMENT
Patient came to Apollo speciality bospital for further treatment. Patient was treated with Cyberknife boost and IMRT after discussion through our tumour board
Now follow MRI revealed good regression of size of tumour and volume analysis showed almost close to 40 to 50 % of reduction in tumour volume.
For more information you may blog your comments or write to lakshmipriya_b@apollohospitals.com
INDICATIONS FOR CYBERKNIFE TREATMENT
The indications for which cyberknife treatment could be useful is indicated below : Dr.Rathna devi, Senior consultant, Radiation oncology
Intra Cranial Tumours – Indications
• Skull base Tumours
• Meningiomas
• Brain Metastases
• Acoustic Schwannoma
• AVM
• Pituitary adenoma
• Low/Hi grade Glioma
Boost Re- irradiation
• Functional
• Trigeminal Neuralgia
• Spinal Tumors - Primary
Re irradiation - Metastases
• Craniophrangioma
• Chordoma
• Hamartoma
• Harmangio blastoma
• Glomus Jugular Tumor
• Boost for Nasopharynx carcinoma
EXTRA CRANIAL SITES – INDICATIONS
. Lung - Primary
- Metastases
• Liver - Primary
- Metastases
• Head & Neck - Tonsil
(Re Irradiation) - Larynx
- Pharynx
- Lacrimal Gland
• Sino Nasal Carcinoma - Boost
- Re –irradiation
• Carcinoma Pancreas
• Carcinoma Gall Bladder
• Para arotic lymph nodes
• Melanoma
• Carcinoma prostate
• Recurrent Orbital Tumours Renal Tumours
• Soft tissue sarcoma
To find out if a particular condition qualifies for cyberknife treatment you may please blog your comments or send in your query to lakshmipriya_b@apollohospitals.com
Intra Cranial Tumours – Indications
• Skull base Tumours
• Meningiomas
• Brain Metastases
• Acoustic Schwannoma
• AVM
• Pituitary adenoma
• Low/Hi grade Glioma
Boost Re- irradiation
• Functional
• Trigeminal Neuralgia
• Spinal Tumors - Primary
Re irradiation - Metastases
• Craniophrangioma
• Chordoma
• Hamartoma
• Harmangio blastoma
• Glomus Jugular Tumor
• Boost for Nasopharynx carcinoma
EXTRA CRANIAL SITES – INDICATIONS
. Lung - Primary
- Metastases
• Liver - Primary
- Metastases
• Head & Neck - Tonsil
(Re Irradiation) - Larynx
- Pharynx
- Lacrimal Gland
• Sino Nasal Carcinoma - Boost
- Re –irradiation
• Carcinoma Pancreas
• Carcinoma Gall Bladder
• Para arotic lymph nodes
• Melanoma
• Carcinoma prostate
• Recurrent Orbital Tumours Renal Tumours
• Soft tissue sarcoma
To find out if a particular condition qualifies for cyberknife treatment you may please blog your comments or send in your query to lakshmipriya_b@apollohospitals.com
Stereotactic body radiotherapy for low-risk prostrate cancer
Stereotactic body radiotherapy for
low-risk prostate cancer:
five-year outcomes
Debra E. Freeman1 and Christopher R. King2
1 Naples Radiation Oncology, PA, USA
2 Department of Radiation Oncology, UCLA School of Medicine, CA, USA
Radiation Oncology 2011, 6:3doi:10.1186/1748-717X-6-3
Purpose
Hypofractionated, stereotactic body radiotherapy (SBRT) is an emerging treatment approach for prostate cancer. We present the outcomes for low-risk prostate cancer patients with a median follow-up of 5 years after SBRT.
Method and Materials
Between Dec. 2003 and Dec. 2005, a pooled cohort of 41 consecutive patients from Stanford, CA and Naples, FL received SBRT with CyberKnife for clinically localized, low-risk prostate cancer. Prescribed dose was 35-36.25 Gy in five fractions. No patient received hormone therapy. Kaplan-Meier biochemical progression-free survival (defined using the Phoenix method) and RTOG toxicity outcomes were assessed.
Results
At a median follow-up of 5 years, the biochemical progression-free survival was 93% (95% CI = 84.7% to 100%). Acute side effects resolved within 1-3 months of treatment completion. There were no grade 4 toxicities. No late grade 3 rectal toxicity occurred, and only one late grade 3 genitourinary toxicity occurred following repeated
urologic instrumentation.
Conclusion
Five-year results of SBRT for localized prostate cancer demonstrate the efficacy and safety of shorter courses of high dose per fraction radiation delivered with SBRT technique. Ongoing clinical trials are underway to further explore this treatment approach.
Source: www.accuray.com
For moreinformation you may blog your comments or write to lakshmipriya_b@apollohospitals.com
low-risk prostate cancer:
five-year outcomes
Debra E. Freeman1 and Christopher R. King2
1 Naples Radiation Oncology, PA, USA
2 Department of Radiation Oncology, UCLA School of Medicine, CA, USA
Radiation Oncology 2011, 6:3doi:10.1186/1748-717X-6-3
Purpose
Hypofractionated, stereotactic body radiotherapy (SBRT) is an emerging treatment approach for prostate cancer. We present the outcomes for low-risk prostate cancer patients with a median follow-up of 5 years after SBRT.
Method and Materials
Between Dec. 2003 and Dec. 2005, a pooled cohort of 41 consecutive patients from Stanford, CA and Naples, FL received SBRT with CyberKnife for clinically localized, low-risk prostate cancer. Prescribed dose was 35-36.25 Gy in five fractions. No patient received hormone therapy. Kaplan-Meier biochemical progression-free survival (defined using the Phoenix method) and RTOG toxicity outcomes were assessed.
Results
At a median follow-up of 5 years, the biochemical progression-free survival was 93% (95% CI = 84.7% to 100%). Acute side effects resolved within 1-3 months of treatment completion. There were no grade 4 toxicities. No late grade 3 rectal toxicity occurred, and only one late grade 3 genitourinary toxicity occurred following repeated
urologic instrumentation.
Conclusion
Five-year results of SBRT for localized prostate cancer demonstrate the efficacy and safety of shorter courses of high dose per fraction radiation delivered with SBRT technique. Ongoing clinical trials are underway to further explore this treatment approach.
Source: www.accuray.com
For moreinformation you may blog your comments or write to lakshmipriya_b@apollohospitals.com
Subscribe to:
Posts (Atom)